{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:20:52Z","timestamp":1793683252576,"version":"4.5.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.urolonc.2025.03.024","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T07:21:12Z","timestamp":1746429672000},"page":"520.e1-520.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intravesical gemcitabine and docetaxel in patients with recurrent high-grade nonmuscle invasive bladder cancer\u2014A prospective cohort study"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5392-4245","authenticated-orcid":false,"given":"Olga M.","family":"Pijpers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarianne G.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle C.","family":"van Diepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joni Y.","family":"Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnout R.","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahlita C.M.","family":"Zuiverloon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim E.M","family":"van Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost L.","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.03.024_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0002","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0004","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0005","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0006","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bju.16303","article-title":"Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations","volume":"134","author":"Holmberg","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0007","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","article-title":"100 years of Bacillus Calmette-Guerin immunotherapy: from cattle to COVID-19","volume":"18","author":"Lobo","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0008","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0009","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.eururo.2012.02.028","article-title":"Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients","volume":"61","author":"Hautmann","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","article-title":"Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology","volume":"55","author":"Shabsigh","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0011","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.euros.2022.12.016","article-title":"Patient preferences for treatment of Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: a cross-country choice experiment","volume":"49","author":"Collacott","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"10.1016\/j.urolonc.2025.03.024_bib0012","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.euo.2024.05.012","article-title":"Novel delivery systems and pharmacotherapeutic approaches for the treatment of non-muscle-invasive bladder cancer","volume":"7","author":"Guerrero-Ramos","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0013","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-Institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0014","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with Bacillus Calmette-Guerin-exposed high-risk non-muscle-invasive Bladder Cancer","volume":"82","author":"Roumiguie","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential Intravesical Gemcitabine and Docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0016","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Version 5: US Department of health and human services; 2017.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed on: 21 April, 2025."},{"key":"10.1016\/j.urolonc.2025.03.024_bib0017","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.eururo.2018.12.014","article-title":"Guidelines for reporting of statistics for clinical research in urology","volume":"75","author":"Assel","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0018","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0019","unstructured":"Chemohyperthermie bij niet-spierinvasief blaascarcinoom, Zorginstituut Nederland, 12 October 2021.https:\/\/www.zorginstituutnederland.nl\/publicaties\/standpunten\/2021\/10\/12\/standpunt-chemohyperthermie-bij-nmibc[10-04-2025]."},{"key":"10.1016\/j.urolonc.2025.03.024_bib0020","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0021","doi-asserted-by":"crossref","first-page":"62.e13","DOI":"10.1016\/j.urolonc.2021.07.019","article-title":"Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer","volume":"40","author":"Pijpers","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0022","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0023","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0024","article-title":"Eugene Kramolowsky IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","author":"Karim Chamie","year":"2022","journal-title":"NEJM Evidence"},{"issue":"4","key":"10.1016\/j.urolonc.2025.03.024_bib0025","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.eururo.2024.05.027","article-title":"Challenging the paradigm of \u201cBCG-unresponsive\u201d bladder cancer: does additional Bacillus Calmette-Gu\u00e9rin have an effect?","volume":"86","author":"Myers","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0026","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JU.0000000000003977","article-title":"A phase 2 trial of intravesical Gemcitabine and Docetaxel in the treatment of Bacillus Calmette-Guerin\u2012naive nonmuscle-invasive urothelial carcinoma of the bladder","volume":"212","author":"Patel","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0027","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.21037\/tau-20-1333","article-title":"Quality of life in patients undergoing surveillance for non-muscle invasive bladder cancer-a systematic review","volume":"10","author":"Nayak","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0028","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.euf.2023.06.006","article-title":"Background and update for ECOG-ACRIN EA8212: a randomized phase 3 trial of intravesical Bacillus Calmette-Guerin (BCG) versus intravesical Docetaxel and Gemcitabine treatment in BCG-naive high-grade non-muscle-invasive bladder cancer (BRIDGE)","volume":"9","author":"Kates","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2025.03.024_bib0029","doi-asserted-by":"crossref","unstructured":"Scilipoti P, Moschini M, Li R, et al. The Financial Burden of Localized and Metastatic Bladder Cancer. Eur Urol. 2024;26:S0302-2838(24)02744\u20131.https:\/\/doi.org\/10.1016\/j.eururo.2024.12.002.","DOI":"10.1016\/j.eururo.2024.12.002"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:35:18Z","timestamp":1754912118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925001243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1078143925001243"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.03.024","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravesical gemcitabine and docetaxel in patients with recurrent high-grade nonmuscle invasive bladder cancer\u2014A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}